197 related articles for article (PubMed ID: 19833135)
1. Protein interaction network analysis--approach for potential drug target identification in Mycobacterium tuberculosis.
Kushwaha SK; Shakya M
J Theor Biol; 2010 Jan; 262(2):284-94. PubMed ID: 19833135
[TBL] [Abstract][Full Text] [Related]
2. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis.
Anishetty S; Pulimi M; Pennathur G
Comput Biol Chem; 2005 Oct; 29(5):368-78. PubMed ID: 16213791
[TBL] [Abstract][Full Text] [Related]
3. Observing local and global properties of metabolic pathways: 'load points' and 'choke points' in the metabolic networks.
Rahman SA; Schomburg D
Bioinformatics; 2006 Jul; 22(14):1767-74. PubMed ID: 16682421
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
5. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
6. T-iDT : tool for identification of drug target in bacteria and validation by Mycobacterium tuberculosis.
Singh NK; Selvam SM; Chakravarthy P
In Silico Biol; 2006; 6(6):485-93. PubMed ID: 17518759
[TBL] [Abstract][Full Text] [Related]
7. Global protein-protein interaction network in the human pathogen Mycobacterium tuberculosis H37Rv.
Wang Y; Cui T; Zhang C; Yang M; Huang Y; Li W; Zhang L; Gao C; He Y; Li Y; Huang F; Zeng J; Huang C; Yang Q; Tian Y; Zhao C; Chen H; Zhang H; He ZG
J Proteome Res; 2010 Dec; 9(12):6665-77. PubMed ID: 20973567
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Potential non homologous protein targets of mycobacterium tuberculosis H37Rv identified from protein-protein interaction network.
Melak T; Gakkhar S
J Theor Biol; 2014 Nov; 361():152-8. PubMed ID: 25106794
[TBL] [Abstract][Full Text] [Related]
10. Strategies for efficient disruption of metabolism in Mycobacterium tuberculosis from network analysis.
Raman K; Vashisht R; Chandra N
Mol Biosyst; 2009 Dec; 5(12):1740-51. PubMed ID: 19593474
[TBL] [Abstract][Full Text] [Related]
11. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis.
Anurag M; Dash D
Mol Biosyst; 2009 Dec; 5(12):1752-7. PubMed ID: 19763328
[TBL] [Abstract][Full Text] [Related]
14. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.
Fakhar Z; Naiker S; Alves CN; Govender T; Maguire GE; Lameira J; Lamichhane G; Kruger HG; Honarparvar B
J Biomol Struct Dyn; 2016 Nov; 34(11):2399-417. PubMed ID: 26612108
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential drug targets in Yersinia pestis using metabolic pathway analysis: MurE ligase as a case study.
Sharma A; Pan A
Eur J Med Chem; 2012 Nov; 57():185-95. PubMed ID: 23059547
[TBL] [Abstract][Full Text] [Related]
16. Differential genome analyses of metabolic enzymes in Pseudomonas aeruginosa for drug target identification.
Perumal D; Lim CS; Sakharkar KR; Sakharkar MK
In Silico Biol; 2007; 7(4-5):453-65. PubMed ID: 18391237
[TBL] [Abstract][Full Text] [Related]
17. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation.
Prathipati P; Ma NL; Manjunatha UH; Bender A
J Proteome Res; 2009 Jun; 8(6):2788-98. PubMed ID: 19301903
[TBL] [Abstract][Full Text] [Related]
18. Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in Mycobacterium tuberculosis, and its application to assessment of drug targets.
Singh VK; Ghosh I
Theor Biol Med Model; 2006 Aug; 3():27. PubMed ID: 16887020
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37Rv.
Lin X; Xu S; Yang Y; Wu J; Wang H; Shen H; Wang H
Protein Expr Purif; 2009 Mar; 64(1):8-15. PubMed ID: 18952181
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
